KeasClinical Studies ApS: Financial statements 2025
CVR: 40794492
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
KeasClinical Studies ApS (CVR 40794492) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -23,492 and a net result of DKK -14,372 compared with DKK -607 the year before. Equity in the 2025 report amounted to DKK 78,298. The solvency ratio was 58%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -23,492
- Profit/Loss
- DKK -14,372
- Equity
- DKK 78,298
- Total Assets
- DKK 134,954
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -23 t. | -14 t. | 78 t. | 1 |
| 2024 | - | -658 | -607 | 93 t. | - |
| 2023 | - | -8 t. | -7 t. | 93 t. | - |
| 2022 | - | -23 t. | -10 t. | 303 t. | - |
| 2021 | - | 151 t. | 113 t. | 663 t. | 0 |
Official annual report
How creditworthy is KeasClinical Studies ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
KeasClinical Studies ApS has published its annual report for 2024. Gross profit came to DKK -658, and the net result was DKK -607.
About KeasClinical Studies ApS
KeasClinical Studies ApS is a Danish company of the type Anpartsselskab based in Aarhus C, founded in 2019. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The company was previously named Blitz Technology ApS. The management consists of Lone Bliksted Gitz-Johansen. The company is owned by Mette Albinus Grønbæk and Blitz Holding ApS. The company has 1 employee (2020). In 2025, the company reported a gross profit of DKK -23,492 and a net result of DKK -14,372 compared with DKK -607 the year before. Equity in the 2025 report amounted to DKK 78,298.